Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T

Investigative Radiology

Volumn 41, Issue 3, 2006, Pages 256-263

  Essig, Marco ^a   Lodemann, Klaus Peter ^b   Le Huu, Martin ^a   Brüning, Roland ^c   Kirchin, Miles ^d   Reith, Wolfgang ^e  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Bracco Altana Pharma   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Bracco SpA   (Italy)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

CBF; CBV; Contrast media; Magnetic resonance imaging; Perfusion

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOBUTROL; CONTRAST MEDIUM; DRUG DERIVATIVE; GADOLINIUM DO3A BUTRIOL; GADOLINIUM-DO3A-BUTRIOL; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; BODY WEIGHT; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN PERFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; GRAY MATTER; HUMAN; IMAGE QUALITY; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITATIVE VALIDITY; QUANTITATIVE ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STANDARDIZATION; STATISTICAL ANALYSIS; WHITE MATTER; BRAIN; BRAIN MAPPING; COMPARATIVE STUDY; METHODOLOGY; NONPARAMETRIC TEST; VASCULARIZATION;

ADULT; BRAIN; BRAIN MAPPING; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; STATISTICS, NONPARAMETRIC;

EID: 33646551152     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000191333.19068.6b     Document Type: Article

References (27)

1. Grandin CB, Duprez TP, Smith AM, et al. Which MR-derived perfusion parameters are the best predictors of infarct growth in hyperacute stroke? Comparative study between relative and quantitative measurements. Radiology. 2002;223:361-370.
2. Martel AL, Allder SJ, Delay GS, et al. Perfusion MRI of infarcted and noninfarcted brain tissue in stroke: a comparison of conventional hemodynamic imaging and factor analysis of dynamic studies. Invest Radiol. 2001;36:378-385.
3. Knopp EA, Cha S, Mazumdar A, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology. 1999;211:791-798.
4. Fuss M, Wenz F, Scholdei R, et al. Radiation-induced regional cerebral blood volume (rCBV) changes in normal brain and low-grade astrocytomas: quantification and time and dose-dependent occurrence. Int J Radiat Oncol Biol Phys. 2000;48:53-58.
5. Rowley HA, Roberts TP. Clinical perspectives in perfusion: neuroradiologic applications. Top Magn Reson Imaging. 2004;15:28-40.
6. Zierler KL. Circulation times and the theory of indicator-dilution methods for determining blood flow and volume. In: Handbook of Physiology. Baltimore: Williams & Wilkins; 1962:585-615.
7. Rempp KA, Brix G, Wenz F, et al. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. Radiology. 1994;193:637-641.
8. van Osch MJ, Vonken EJ, Bakker CJ, et al. Correcting partial volume artifacts of the arterial input function in quantitative cerebral perfusion MRI. Magn Reson Med. 2001;45:477-485.
9. Østergaard L, Sorensen AG, Kwong KK, et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: experimental comparison and preliminary results. Magn Reson Med. 1996;36:726-736.
10. Benner T, Heiland S, Erb G, et al. Accuracy of gamma-variate fits to concentration-time curves from dynamic susceptibility-contrast enhanced MRI: influence of time resolution, maximal signal drop and signal-to-noise. Magn Reson Imaging. 1997;15:307-317.
11. Pomper MG, Port JD. New techniques in MR imaging of brain tumors. Magn Reson Imaging Clin N Am. 2000;8:691-713.
12. Lev MH, Rosen BR. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am. 1999;9:309-331.
13. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
14. Tombach B, Benner T, Reimer P, et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology. 2003;226:880-888.
15. de Haën C, Cabrini M, Akhnana L, et al. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®): pharmaceutical-formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999;23(suppl 1):S161-S168.
16. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol. 1999;6:282-291.
17. Colosimo C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol. 2001;36:72-81.
18. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004;230:55-64.
19. Colosimo C, Knopp MV, Barreau X, et al. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology. 2004;46:655-665.
20. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging. 2003;14:426-435.
21. Bruning R, Weber J, Wu RH, et al. Echo-planar imaging of the brain. Radiologe. 1995;35:902-910.
22. Bozzao A, Floris R, Baviera ME, et al. Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. AJNR Am J Neuroradiol. 2001;22:1030-1036.
23. Manka C, Träber F, Gieseke J, et al. Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3 T: feasibility and contrast agent dose. Radiology. 2005;234:869-877.
24. Sorensen AG, Tievsky AL, Ostergaard L, et al. Contrast agents in functional MR imaging. J Magn Reson Imaging. 1997;7:47-55.
25. Runge VM, Kirsch JE, Wells JW, et al. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study. AJR Am J Roentgenol. 1993;160:593-600.
26. Boxerman JL, Rosen BR, Weisskoff RM. Signal-to-noise analysis of cerebral blood volume maps from dynamic NMR imaging studies. J Magn Reson Imaging. 1997;7:528-537.
27. Port M, Corot C, Violas X, et al. How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity. Invest Radiol. 2005;40:565-573.